Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema

Objective: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg intravitreal implant for the treatment of clinically significant chronic diabetic macular edema (DME) in routine clinical practice. Methods:...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2017-10, Vol.33 (sup2), p.5-17
Main Authors: Holden, Sarah E., Currie, Craig J., Owens, David R.
Format: Article
Language:English
Subjects:
Aged
diabetic macular edema
Diabetic Retinopathy - drug therapy
Drug Implants
Female
Fluocinolone acetonide
Fluocinolone Acetonide - therapeutic use
Glucocorticoids - therapeutic use
Humans
Intraocular Pressure
Macular Edema - drug therapy
Male
Middle Aged
retrospective
Retrospective Studies
Treatment Outcome
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg intravitreal implant for the treatment of clinically significant chronic diabetic macular edema (DME) in routine clinical practice. Methods: This retrospective study collected data from patient medical records in 13 ophthalmology centers for people with DME prescribed FAc intravitreal implant between April 1, 2013 and April 15, 2015. Visual acuity (VA) and intraocular pressure (IOP) measurements were collected for 12 months prior to and after implant. Results: Two hundred and eight people, contributing 233 eyes, treated with FAc implant were included. Mean age was 68.1 years and 62% were male. In the 12 months prior to FAc implant, VA declined. Median (interquartile range, IQR) VA was 0.66 (0.48-1.00) LogMAR units (equivalent to 52.0 ETDRS letters) at implant, improving to 0.60 (0.38-0.90) LogMAR units (55.0 letters) at 12 months post-implant (p 
ISSN:0300-7995
1473-4877
DOI:10.1080/03007995.2017.1366645